Positive News SentimentPositive NewsNASDAQ:IPSC Century Therapeutics (IPSC) Stock Forecast, Price & News $2.03 -0.07 (-3.33%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.00▼$2.1650-Day Range$2.03▼$3.2352-Week Range$2.00▼$11.95Volume97,568 shsAverage Volume134,653 shsMarket Capitalization$121.31 millionP/E RatioN/ADividend YieldN/APrice Target$15.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Century Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside655.3% Upside$15.33 Price TargetShort InterestHealthy2.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.87Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.02) to ($1.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector357th out of 964 stocksBiological Products, Except Diagnostic Industry54th out of 159 stocks 3.4 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.33, Century Therapeutics has a forecasted upside of 655.3% from its current price of $2.03.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.67% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Century Therapeutics has recently decreased by 14.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 3.8 News and Social Media Coverage News SentimentCentury Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Century Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for IPSC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Century Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.28% of the stock of Century Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to grow in the coming year, from ($2.02) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Century Therapeutics (NASDAQ:IPSC) StockCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More IPSC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comCentury Therapeutics to Present at the Chardan 7th Annual Genetic Medicines ConferenceSeptember 10, 2023 | thestreet.comCentury Therapeutics Inc.September 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 29, 2023 | msn.comJP Morgan Downgrades Century Therapeutics (IPSC)August 28, 2023 | msn.comJP Morgan cuts Century Therapeutics to neutral, cites lengthy data timelineAugust 11, 2023 | msn.comPiper Sandler Maintains Century Therapeutics (IPSC) Overweight RecommendationAugust 11, 2023 | msn.comEF Hutton Reiterates Century Therapeutics (IPSC) Buy RecommendationAugust 10, 2023 | msn.comChardan Capital Maintains Century Therapeutics (IPSC) Buy RecommendationSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 10, 2023 | msn.comHC Wainwright & Co. Maintains Century Therapeutics (IPSC) Buy RecommendationAugust 10, 2023 | benzinga.comThese Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 ResultsAugust 9, 2023 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 9, 2023 | finance.yahoo.comCentury Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 9, 2023 | finance.yahoo.comCentury Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue EstimatesAugust 1, 2023 | finance.yahoo.comCentury Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year agoMay 12, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Century Therapeutics (IPSC)May 12, 2023 | finance.yahoo.comCentury Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 11, 2023 | msn.comCentury Therapeutics: Q1 Earnings InsightsMay 11, 2023 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 11, 2023 | finance.yahoo.comCentury Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue EstimatesMay 11, 2023 | finance.yahoo.comCentury Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesApril 17, 2023 | benzinga.comCentury Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual SummitApril 13, 2023 | msn.comHC Wainwright & Co. Reiterates Century Therapeutics (IPSC) Buy RecommendationApril 13, 2023 | markets.businessinsider.comAnalyst Ratings for Century TherapeuticsApril 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Brainsway (BWAY) and Century Therapeutics (IPSC)April 12, 2023 | msn.comCentury Therapeutics CEO Lalo Flores steps down, Greg Russotti appointed as ad-interim Chief Executive OfficerApril 12, 2023 | bizjournals.comCentury Therapeutics CEO departs amid shakeup in C-suiteSee More Headlines Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSC Company Calendar Last Earnings8/09/2023Today9/26/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.33 High Stock Price Forecast$28.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+651.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,930,000.00 Net Margins-2,782.34% Pretax Margin-2,733.81% Return on Equity-43.88% Return on Assets-27.14% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual Sales$5.20 million Price / Sales23.44 Cash FlowN/A Price / Cash FlowN/A Book Value$5.13 per share Price / Book0.40Miscellaneous Outstanding Shares59,760,000Free Float55,223,000Market Cap$121.91 million OptionableNot Optionable Beta0.66 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Michael C. Diem M.D. (Age 52)Chief Financial Officer Comp: $650.66kDr. Adrienne Farid Ph.D. (Age 61)COO & Head of Early Devel. Comp: $650.66kDr. Gregory Russotti Ph.D. (Age 56)Interim Pres & CEO Mr. Kenneth J. Dow J.D.Sr. VP of Gen. CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 65)Pres of R&D Michael Naso Ph.D.Sr. VP of Cell EngineeringMr. Douglas Carr CPASr. VP of Fin. & Operations and Sec.More ExecutivesKey CompetitorsGritstone bioNASDAQ:GRTSINmune BioNASDAQ:INMBOrchard TherapeuticsNASDAQ:ORTXERYTECH PharmaNASDAQ:ERYPTScan TherapeuticsNASDAQ:TCRXView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Sold 9,757 shares on 8/15/2023Ownership: 0.072%Wells Fargo & Company MNBought 5,321 shares on 8/15/2023Ownership: 0.015%Citadel Advisors LLCSold 2,000 shares on 8/15/2023Ownership: 0.000%State Street CorpBought 85,940 shares on 8/14/2023Ownership: 0.761%State of Wisconsin Investment BoardSold 5,600 shares on 8/14/2023Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions IPSC Stock - Frequently Asked Questions Should I buy or sell Century Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks. What is Century Therapeutics' stock price forecast for 2023? 8 Wall Street research analysts have issued 1-year price targets for Century Therapeutics' stock. Their IPSC share price forecasts range from $5.00 to $28.00. On average, they predict the company's stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 651.6% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts. How have IPSC shares performed in 2023? Century Therapeutics' stock was trading at $5.13 at the beginning of the year. Since then, IPSC stock has decreased by 60.2% and is now trading at $2.04. View the best growth stocks for 2023 here. Are investors shorting Century Therapeutics? Century Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 642,200 shares, a drop of 14.0% from the August 15th total of 747,100 shares. Based on an average daily trading volume, of 100,600 shares, the days-to-cover ratio is currently 6.4 days. Approximately 2.7% of the company's shares are sold short. View Century Therapeutics' Short Interest. When is Century Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our IPSC earnings forecast. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.02. The firm earned $0.10 million during the quarter, compared to analyst estimates of $1.54 million. Century Therapeutics had a negative net margin of 2,782.34% and a negative trailing twelve-month return on equity of 43.88%. When did Century Therapeutics IPO? (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. What is Century Therapeutics' stock symbol? Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC." Who are Century Therapeutics' major shareholders? Century Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.71%), State Street Corp (0.76%), Geode Capital Management LLC (0.74%), Northern Trust Corp (0.30%), Charles Schwab Investment Management Inc. (0.27%) and New York Life Investment Management LLC (0.20%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Century Therapeutics' stock price today? One share of IPSC stock can currently be purchased for approximately $2.04. How much money does Century Therapeutics make? Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $121.91 million and generates $5.20 million in revenue each year. The company earns $-130,930,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. How many employees does Century Therapeutics have? The company employs 163 workers across the globe. How can I contact Century Therapeutics? The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com. This page (NASDAQ:IPSC) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.